CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 5, 2006--Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, today announced the presentation of preclinical research suggesting the potential of the Company’s lead product candidate, depsipeptide (FK228), in combination with gemcitabine, as a treatment for pancreatic adenocarcinoma. The findings were reported at the 97th Annual Meeting of the American Association of Cancer Research (AACR), taking place in Washington, DC. Full text of the abstract #3829 “In Vivo Evaluation of Depsipeptide (FK228) Alone or in Combination with Gemcitabine in Two Human Pancreas Tumor Xenograft Models” can be viewed on the AACR website at www.aacr.org. The study was co-sponsored by the Cancer Therapy and Research Center Institute for Drug Development in San Antonio, Texas and Gloucester Pharmaceuticals.
